JP2023505318A5 - - Google Patents

Info

Publication number
JP2023505318A5
JP2023505318A5 JP2022534370A JP2022534370A JP2023505318A5 JP 2023505318 A5 JP2023505318 A5 JP 2023505318A5 JP 2022534370 A JP2022534370 A JP 2022534370A JP 2022534370 A JP2022534370 A JP 2022534370A JP 2023505318 A5 JP2023505318 A5 JP 2023505318A5
Authority
JP
Japan
Prior art keywords
antibody
domain
antibodies
derived
scfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022534370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505318A (ja
JP7641967B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/084831 external-priority patent/WO2021111003A1/en
Publication of JP2023505318A publication Critical patent/JP2023505318A/ja
Publication of JP2023505318A5 publication Critical patent/JP2023505318A5/ja
Application granted granted Critical
Publication of JP7641967B2 publication Critical patent/JP7641967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022534370A 2019-12-06 2020-12-07 ヒト化cldn18.2抗体 Active JP7641967B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214104 2019-12-06
EP19214104.2 2019-12-06
PCT/EP2020/084831 WO2021111003A1 (en) 2019-12-06 2020-12-07 Humanized cldn18.2 antibodies

Publications (3)

Publication Number Publication Date
JP2023505318A JP2023505318A (ja) 2023-02-08
JP2023505318A5 true JP2023505318A5 (cg-RX-API-DMAC7.html) 2023-10-24
JP7641967B2 JP7641967B2 (ja) 2025-03-07

Family

ID=68808161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534370A Active JP7641967B2 (ja) 2019-12-06 2020-12-07 ヒト化cldn18.2抗体

Country Status (8)

Country Link
US (1) US12624100B2 (cg-RX-API-DMAC7.html)
EP (1) EP4069738A1 (cg-RX-API-DMAC7.html)
JP (1) JP7641967B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220111308A (cg-RX-API-DMAC7.html)
CN (1) CN114901696B (cg-RX-API-DMAC7.html)
AU (1) AU2020398045A1 (cg-RX-API-DMAC7.html)
CA (1) CA3159465A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021111003A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230124037A (ko) * 2020-12-23 2023-08-24 소티오 바이오테크 에이.에스. 종양 특이적 claudin 18.2 항체-약물 접합체
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
EP4349371A4 (en) 2021-06-02 2025-06-25 Bio-Thera Solutions, Ltd. DRUG CONJUGATE AND USE THEREOF
JP7901102B2 (ja) * 2021-06-15 2026-08-05 ゼンコア インコーポレイテッド クローディン18.2及びcd3に結合するヘテロ二量体抗体
US20240350589A1 (en) 2021-08-13 2024-10-24 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025078686A1 (en) 2023-10-12 2025-04-17 Sotio Biotech A.S. Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer
WO2025077829A1 (zh) * 2023-10-13 2025-04-17 信达细胞制药(苏州)有限公司 Cldn18.2抗体及car-t细胞在治疗cldn18.2阳性实体瘤中的应用
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1112364A2 (en) 1998-09-16 2001-07-04 ZymoGenetics, Inc. Stomach polypeptide zsig28
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
IL282953B2 (en) 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014145444A1 (en) * 2013-03-15 2014-09-18 Pilltek Llc Systems, methods, and apparatuses for securely dispensing one or more prescribed substances to a securely identified intended user
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2018006882A1 (zh) 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
CN109970857B (zh) * 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
MX2020009326A (es) * 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.
WO2019175617A1 (en) 2018-03-10 2019-09-19 Pratik Sharma Data redundancy and elimination module
CA3087423A1 (en) 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
CN116178554B (zh) 2018-05-18 2025-09-09 礼新医药科技(上海)有限公司 抗密蛋白18.2抗体及其用途
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
BR112022012327A2 (pt) * 2019-12-23 2022-10-18 Sotio Biotech A S Anticorpos ou fragmentos dos mesmos, ácido nucleico, vetor e célula hospedeira
WO2022122709A1 (en) * 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
KR20230124037A (ko) * 2020-12-23 2023-08-24 소티오 바이오테크 에이.에스. 종양 특이적 claudin 18.2 항체-약물 접합체
JP2024524891A (ja) * 2021-06-23 2024-07-09 サイチューン ファーマ インターロイキン-15に基づく免疫サイトカイン
US20240350589A1 (en) * 2021-08-13 2024-10-24 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
US12614475B2 (en) * 2023-09-06 2026-04-28 Ford Global Technologies, Llc Systems and methods for facilitating touring in a vehicle
WO2025078686A1 (en) * 2023-10-12 2025-04-17 Sotio Biotech A.S. Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer

Similar Documents

Publication Publication Date Title
JP7651031B2 (ja) Cdrのアミノ酸置換により抗体の等電点を改変する方法
JP7550591B2 (ja) 多重特異的NKp46結合タンパク質
US10494446B2 (en) Readily isolated bispecific antibodies with native immunoglobulin format
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール(miniGNC)抗体様タンパク質、その製造方法及び使用方法
Krah et al. Engineering bispecific antibodies with defined chain pairing
JP2025142045A5 (cg-RX-API-DMAC7.html)
Labrijn et al. When binding is enough: nonactivating antibody formats
JP7822587B2 (ja) ヘテロ二量体化Igドメイン
Caravella et al. Design of next-generation protein therapeutics
JP2022537931A5 (cg-RX-API-DMAC7.html)
JP2016514676A (ja) 四価二重特異性抗体
CN109796532B (zh) 靶向成纤维激活蛋白α的结合单元及其应用
JP2024532482A5 (cg-RX-API-DMAC7.html)
CA3079363A1 (en) Multispecific antigen binding proteins
US20180371088A1 (en) TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY
US20200354457A1 (en) Bispecific antibodies comprising an antigen-binding site binding to lag3
JP2024515301A5 (cg-RX-API-DMAC7.html)
US20250243274A1 (en) Compositions for Redirecting Immunoglobulins to Immune Cells
JP2021519589A5 (cg-RX-API-DMAC7.html)